Article Per Year (5 Year)
p-Index From 2020 - 2025
2.81
P-Index
This Author published in this journals
All Journal HAYATI Journal of Biosciences Medical Journal of Indonesia Indonesian Journal of Cancer Universa Medicina Jurnal Respirologi Indonesia Jurnal Ilmu Kefarmasian Indonesia Jurnal Respirasi (JR) Sumatera Medical Journal JURNAL PENELITIAN KEPERAWATAN MEDIK Respiratory Science Cermin Dunia Kedokteran Indonesian Journal of Cancer eJournal Kedokteran Indonesia
Elisna Syahruddin
Department Of Pulmonology And Respiratory Medicine, Faculty Of Medicine, Universitas Indonesia
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Earth & Planetary Sciences Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health

Published : 30 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search
Journal : eJournal Kedokteran Indonesia

 1 
Observational Study of Paclitaxel-Carboplatin versus Pemetrexed-Carboplatin for Advanced Pulmonary Adenocarcinoma at Single-Centre in Indonesia Rianyta Rianyta; Melva Louisa; Elisna Syahruddin; Vivian Soetikno
eJournal Kedokteran Indonesia Vol 9, No. 3 - Desember 2021
Publisher : Faculty of Medicine Universitas Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (224.216 KB) | DOI: 10.23886/ejki.9.16.178-86

Abstract

Platinum-based chemotherapy regimens with two types of drugs, such as paclitaxel-carboplatin and pemetrexedcarboplatin, are first-line therapy for pulmonary adenocarcinoma patients with negative epidermal growth factor receptor (EGFR) mutation. This study aimed to determine the efficacy, toxicity, and cost profile of paclitaxel-carboplatin compared to pemetrexed-carboplatin. This is a cross-sectional study. Pulmonary adenocarcinoma negative EGFR mutation naïve patients treated with paclitaxel-carboplatin or pemetrexed-carboplatin were included. Effectiveness was assessed based on the overall response rate (ORR) according to the response evaluation criteria in solid tumours (RECIST). A pharmacoeconomic analysis is performed based on clinical outcomes consisting of effectiveness and direct medical costs. Medical records from 21 patients with paclitaxel-carboplatin and 21 patients with pemetrexedcarboplatin were successfully evaluated. The effectiveness of the two chemotherapy regimens was not significantly different (OR, 1.25; 95% confidence interval, 0.34 to 4.64; p = 0.739). Frequent haematological toxicities experienced in the two groups were grade 1-2 anaemia, neutropenia, leukopenia. Grade 3 anaemia, leukopenia, and neutropenia were more common in the paclitaxel-carboplatin group. The two groups’ nonhematological toxicities were nausea vomitus and hair loss, with peripheral neuropathy more experienced by the paclitaxel-carboplatin group. Costminimization analysis reveals that the average cost per patient with pulmonary adenocarcinoma negative EGFR mutation with paclitaxel-carboplatin regimen was cheaper IDR 10,986,257.55 or 50.25%, compared to pemetrexedcarboplatin. In conclusion, there was no significant difference in the effectiveness of the two regimens. The most common adverse effects in both regimens were haematological toxicities. The average cost per patient with a paclitaxel-carboplatin regimen was cheaper compared to pemetrexed-carboplatin.
Co-Authors Abul A'la Al Maududi Afiani, Dina AHMAD HUDOYO Ahmad Hudoyo Ahmad Hudoyo Aldri Frinaldi Alma Thahir Pulungan Ana Rima Ana Rima Setijadi Ananda, Fannie Rizki Andalucia, Rizka Andarini, Sita Andi Yasmon Andreas Infianto Anna Rozaliyani Annisa Dian Harlivasari Anwar Jusuf Anwar Jusuf Arfiansyah, Mochammad Aris Aria Kekalih Arif Faisal ARIF R HANAFI ARIF R HANAFI, ARIF R Arif Santoso Arif Santoso Ath-Thobari, Jarir AZIZA G ICKSAN AZIZA G ICKSAN, AZIZA G Aziza Icksan Aziza Icksan Buana, Indra Budiman Bela Denny Grecius Siregar Dian Cahyadi Dian Yulianti Duyen, Natalie Erlina Burhan Ermayanti, Sabrina Ermayanti, Sabrina Erni Mudhiati EVLINA SUZANNA, EVLINA Fariz, Nurwidya Feni Fitriani Fera Ibrahim Ferry Dwi Kurniawan Findra Setianingrum Fitri Nurhayati GRACE SHALMONT, GRACE Hanif, Muhammad Alfin Haryati Haryati Haryati Haryati Hasbullah Thabrany Heriawaty Hidajat Heriawaty Hidajat, Heriawaty Hidayat, Moulid Ida Ayu Jasminarti Ida Ayu Jasminarti Dwi Kusumawardani Infianto, Andreas Jasminarti, Ida Ayu Kurniawan, Ferry Dwi Laksmi Wulandari Lia G. Partakusuma Lim, Darren Wan-Teck Lisnawati Lisnawati Melva Louisa Mia Elhidsi Mulatsari, Esti Mulyati Tugiran Nathaniel Aditya Noni Novisari Soeroso Novita Andayani, Novita Nurmadani, Labbaika PRADNYA SRI RAHAYU, PRADNYA SRI Pratama, Avissena Dutha Pratiwi, Suryanti Dwi Putra, Andika Chandra Putra, Muhammad Yusuf Adira Rahmat Hidayat Ramadhaniah, Fariha Rianyta Rianyta Ridhawati Sjam Rita Khairani Robiatul Adawiyah Romi Baginta Santoso, Andintia Aisyah Saputra, Tetra Arya Sarah Fitriani Sayekti, Mutia A. Setiaputra Setiaputra Setyawan, Ungky Agus Shanty R. Kusumawardani Sita Andarini Sita Andarini Sita Andarini Soehardiman, Dicky Solly Aryza Sri Melati Munir Sri Melati Munir Steven Jonathan Tamam Anugrah TAMSIL Tarigan, Setia Putra Taufik Ashar Vivian Soetikno Winnugroho Wiratman, Manfaluthy Hakim, Tiara Aninditha, Aru W. Sudoyo, Joedo Prihartono Wira Winardi Yayi DB Susanto Yopi Simargi Yopi Simargi, Yopi Yuliyanti, Sayekti Yusi Anggriani Zahrah Annisa Zaini, Jamal